GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: JEDI-1444 is from a series of antibacterial compounds that target UDP-2,3-diacylglucosamine hydrolase (LpxH), an essential enzyme in the lipopolysaccharide synthesis pathway, that is conserved in the majority of Gram-negative bacteria but absent in human [1]. JEDI-1444 was identified as part of a programme to develop LpxH inhibitors with activity against efflux-proficient Gram-negative bacteria. It was designed by combining structural elements from existing LpxH inhibitors AZ1 and JEDI-852 and was subsequently used to derive improved analogues EBL-3599 and EBL-3647.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| JEDI-1444 exhibits Gram-negative antibacterial activity and is effective against efflux-proficient strains of Escherichia coli and Klebsiella pneumoniae [1]. However, it has weak antibacterial activity in the presence of serum and is also limited by low solubility and poor metabolic stability. JEDI-1444 inhibits E.coli LpxH with an IC50 of 2.6 nM [1]. |